These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23745563)

  • 21. MicroRNAs-Dependent Regulation of PPARs in Metabolic Diseases and Cancers.
    Portius D; Sobolewski C; Foti M
    PPAR Res; 2017; 2017():7058424. PubMed ID: 28167956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual Functional Roles of Molecular Beacon as a MicroRNA Detector and Inhibitor.
    Li WM; Chan CM; Miller AL; Lee CH
    J Biol Chem; 2017 Mar; 292(9):3568-3580. PubMed ID: 28100783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of miRNAs in Common Inflammatory Arthropathies: Osteoarthritis and Gouty Arthritis.
    Papanagnou P; Stivarou T; Tsironi M
    Biomolecules; 2016 Nov; 6(4):. PubMed ID: 27845712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells.
    Taipaleenmäki H; Farina NH; van Wijnen AJ; Stein JL; Hesse E; Stein GS; Lian JB
    Oncotarget; 2016 Nov; 7(48):79032-79046. PubMed ID: 27738322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal Cancers.
    Merhautova J; Demlova R; Slaby O
    Front Pharmacol; 2016; 7():329. PubMed ID: 27729862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pigmy MicroRNA: surveillance cops in Therapies kingdom.
    Bhadra U; Patra P; Chhatai J; Pal-Bhadra M
    Mol Med; 2016 Dec; 22():759-775. PubMed ID: 27704139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrative analysis of signaling pathways and diseases associated with the miR-106b/25 cluster and their function study in berberine-induced multiple myeloma cells.
    Gu C; Li T; Yin Z; Chen S; Fei J; Shen J; Zhang Y
    Funct Integr Genomics; 2017 May; 17(2-3):253-262. PubMed ID: 27647143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment.
    Rupaimoole R; Calin GA; Lopez-Berestein G; Sood AK
    Cancer Discov; 2016 Mar; 6(3):235-46. PubMed ID: 26865249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics.
    Varshney J; Subramanian S
    Front Mol Biosci; 2015; 2():31. PubMed ID: 26137468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.
    Eedunuri VK; Rajapakshe K; Fiskus W; Geng C; Chew SA; Foley C; Shah SS; Shou J; Mohamed JS; Coarfa C; O'Malley BW; Mitsiades N
    Mol Endocrinol; 2015 Aug; 29(8):1170-83. PubMed ID: 26066330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides.
    Ezzat K; Aoki Y; Koo T; McClorey G; Benner L; Coenen-Stass A; O'Donovan L; Lehto T; Garcia-Guerra A; Nordin J; Saleh AF; Behlke M; Morris J; Goyenvalle A; Dugovic B; Leumann C; Gordon S; Gait MJ; El-Andaloussi S; Wood MJ
    Nano Lett; 2015 Jul; 15(7):4364-73. PubMed ID: 26042553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
    Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
    Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNAs--getting the hang of it.
    Lund AH
    Cell Death Differ; 2015 Jan; 22(1):1-2. PubMed ID: 25481979
    [No Abstract]   [Full Text] [Related]  

  • 34. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.
    Cheng CJ; Bahal R; Babar IA; Pincus Z; Barrera F; Liu C; Svoronos A; Braddock DT; Glazer PM; Engelman DM; Saltzman WM; Slack FJ
    Nature; 2015 Feb; 518(7537):107-10. PubMed ID: 25409146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications.
    Stahlhut C; Slack FJ
    Genome Med; 2013; 5(12):111. PubMed ID: 24373327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long Non-Coding RNAs Embedded in the Rb and p53 Pathways.
    Subramanian M; Jones MF; Lal A
    Cancers (Basel); 2013 Dec; 5(4):1655-75. PubMed ID: 24305655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Canonical and non-canonical barriers facing antimiR cancer therapeutics.
    Cheng CJ; Saltzman WM; Slack FJ
    Curr Med Chem; 2013; 20(29):3582-93. PubMed ID: 23745563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of microRNA function by antimiR oligonucleotides.
    Stenvang J; Petri A; Lindow M; Obad S; Kauppinen S
    Silence; 2012 Jan; 3(1):1. PubMed ID: 22230293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MicroRNA therapeutics: principles, expectations, and challenges.
    Rupaimoole R; Han HD; Lopez-Berestein G; Sood AK
    Chin J Cancer; 2011 Jun; 30(6):368-70. PubMed ID: 21627858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The therapeutic potential of microRNAs in cancer.
    Thorsen SB; Obad S; Jensen NF; Stenvang J; Kauppinen S
    Cancer J; 2012; 18(3):275-84. PubMed ID: 22647365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.